The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

Takefumi  Komiya

Honoraria - Boehringer Ingelheim

Research Funding - AstraZeneca (Inst); Merck (Inst)

Travel, Accommodations, Expenses - Merck

Jun  Zhang

Honoraria - AstraZeneca; Biodesix; General Dynamics Information Technology (GDIT)

Consulting or Advisory Role - AstraZeneca; Bayer; Daiichi Sankyo; Novocure

Speakers' Bureau - AstraZeneca; MJH Life Sciences

Research Funding - Abbvie; AstraZeneca; Genentech; Hengrui Therapeutics; Mirati Therapeutics; Novartis

Prakash C.  Neupane

Research Funding - Merck Sharp & Dohme

Kathan  Mehta

Consulting or Advisory Role - Blueprint Medicines; Takeda

Chao Hui  Huang

Stock and Other Ownership Interests  - Vanguard Funds

Honoraria - Ipsen

Consulting or Advisory Role - Biodesix; Ipsen

Research Funding - Bayer (Inst); Benta Pharma Industries (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Regenxbio (Inst)